LIMK1 and breast carcinoma: Hsa-miR-629-5p promotes tumor progression by targeting AKAP13 in prostate cancer44, and hsa-miR-128-3p acts as tumor suppressor in breast cancer by regulating the LIMK1/CFL1 signaling pathway45.